Wet AMD and the Quest for Durable Treatments: Hydrogel-Delivered VEGF Inhibitors

In this podcast, Dr. Nadia Wahid outlines how wet AMD damages the retina, why monthly anti-VEGF injections can fall short, and how durable, sustained-delivery therapies may change patient care.

• Current anti-VEGF therapy slows vision loss but requires frequent injections and strict adherence.
• The real world burden extends to patients and families, especially in older adults facing transport and weather challenges.
• Sustained-delivery approaches like hydrogel based OTX-TKI aim to maintain drug levels for months, reducing clinic visits.
• Future directions focus on limiting fibrosis and atrophy to preserve vision longer.

Overview of wet AMD and current treatment landscape

As people age they become more susceptible to vision loss from age related macular degeneration, a condition in which abnormal blood vessels grow under the retina. The late stage, wet AMD, features fluid or blood leakage that can blur vision and cause scarring. The standard of care has been injections that inhibit VEGF, a key driver of abnormal vessel growth. When used early and consistently these therapies can stop additional vision loss and may improve vision for some patients. However the field has long sought ways to extend the duration of disease control beyond the typical one to three month window. In real world settings, adherence and access affect outcomes, and long term data show progressive vision loss despite frequent injections. Many patients are elderly, may have mobility or driving challenges, and rely on caregivers. The speak with Dr. Wahid highlights the burdens around monthly injections, including trips to the clinic and the practicalities of living with eye dilation and temporary impairment after procedures.

Real world burden of anti VEGF therapy

The conversation emphasizes that even when patients are fairly adherent, there is a pattern of peaks and troughs in drug levels inside the eye. When the drug is at its peak, the disease is well controlled, but as the drug levels wane there can be recurrences of fluid and bleeding. The through line is that this up and down pattern may contribute to gradual declines in visual acuity over many years. Treat and extend strategies have been developed to stretch injection intervals, but waiting for fluid to return can still risk irreversible damage. The podcast also discusses the social and logistical burden of injections, including the fact that many patients are not driving, snow complicates winter travel, and caregivers become central to scheduling and transportation.

Durability and the search for longer acting therapies

Dr Wahid explains that durability in drug delivery for wet AMD is a major focus. A longer acting approach would provide a steady state of drug exposure and minimize the peaks and troughs that accompany current therapies. Two broad mechanisms are being explored, including intracellular inhibitors that disrupt VEGF signaling within the cell and extracellular strategies that prevent VEGF from acting at the surface. The ultimate aim is to deliver reliable and predictable disease control for half a year, nine months, or even a full year with a single intervention, thereby reducing the burden on patients and caregivers while preserving vision more effectively over time.

OTX TKI and hydrogel delivery

The podcast centers on OTX TKI, an intracellular VEGF inhibitor. The drug is delivered in a hydrogel that remains inside the eye for six to nine months and may extend to around a year in some patients. The hydrogel maintains a consistent release of the medication, avoiding the peaks and troughs associated with repeated injections. As the hydrogel dissolves over time, it leaves no residue inside the eye, at which point another intervention might be considered. This approach represents a paradigm shift toward sustained delivery that aligns with physicians’ desire to provide durable disease control with fewer in office visits.

Future directions and patient outcomes

Beyond simply prolonging drug exposure, the long term management of wet AMD faces challenges from fibrosis and atrophy, which can progress independently of vessels. The speaker highlights that durable therapies could help not only preserve vision in the short term but also potentially reduce the development of fibrosis and macular atrophy over 5, 7, and 10 year horizons. Over 10 to 20 years, improvements in longer acting medications could enable better vision upfront and reduce long term structural changes in the retina. The discussion closes with a sense of cautious optimism about the role of durable therapies in transforming the retina patient experience and outcomes.

Closing reflections

Dr. Nadia Wahid emphasizes that the future of wet AMD treatment lies in delivering reliable, longer acting medications that maintain vision and lessen the burden of ongoing injections. The conversation underscores the importance of real world data, patient quality of life, and the possibility that therapies like hydrogel-encapsulated intracellular inhibitors may redefine the standard of care for wet AMD in the coming decades.

Note

The podcast discusses OTX TKI as an investigational product candidate and does not reflect FDA approval status. Safety and effectiveness have not been established.